JP2025502208A5 - - Google Patents

Info

Publication number
JP2025502208A5
JP2025502208A5 JP2024541809A JP2024541809A JP2025502208A5 JP 2025502208 A5 JP2025502208 A5 JP 2025502208A5 JP 2024541809 A JP2024541809 A JP 2024541809A JP 2024541809 A JP2024541809 A JP 2024541809A JP 2025502208 A5 JP2025502208 A5 JP 2025502208A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
indole
ethane
bis
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024541809A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025502208A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/050702 external-priority patent/WO2023135237A1/en
Publication of JP2025502208A publication Critical patent/JP2025502208A/ja
Publication of JP2025502208A5 publication Critical patent/JP2025502208A5/ja
Pending legal-status Critical Current

Links

JP2024541809A 2022-01-14 2023-01-13 トリプタミン組成物および方法 Pending JP2025502208A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263299599P 2022-01-14 2022-01-14
US63/299,599 2022-01-14
US202263384704P 2022-11-22 2022-11-22
US63/384,704 2022-11-22
PCT/EP2023/050702 WO2023135237A1 (en) 2022-01-14 2023-01-13 Tryptamine compositions and methods

Publications (2)

Publication Number Publication Date
JP2025502208A JP2025502208A (ja) 2025-01-24
JP2025502208A5 true JP2025502208A5 (enExample) 2026-01-20

Family

ID=85018123

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024541809A Pending JP2025502208A (ja) 2022-01-14 2023-01-13 トリプタミン組成物および方法

Country Status (9)

Country Link
US (1) US20250051279A1 (enExample)
EP (1) EP4463440A1 (enExample)
JP (1) JP2025502208A (enExample)
KR (1) KR20240134951A (enExample)
AU (1) AU2023207801B2 (enExample)
CA (1) CA3259235A1 (enExample)
IL (1) IL313889A (enExample)
MX (1) MX2024008691A (enExample)
WO (1) WO2023135237A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024108195A1 (en) 2022-11-17 2024-05-23 Remedi, Inc. Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
TW202617141A (zh) 2024-07-10 2026-05-01 英商賽本英國有限公司 包含氘化n,n-二甲基色胺之醫藥組合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
US6488648B1 (en) 1999-01-14 2002-12-03 Teijin Limited Device for feeding a powder in a predetermined amount and method thereof
GB0121568D0 (en) 2001-09-06 2001-10-24 Optinose As Nasal delivery device
NZ514442A (en) 1999-03-03 2003-08-29 Optinose As Nasal delivery device
GB0114272D0 (en) 2001-06-12 2001-08-01 Optinose As Nasal delivery device
GB0019715D0 (en) 2000-08-10 2000-09-27 Pa Consulting Services Device for delivering physiologically active agent in powdered form
ZA200306564B (en) 2001-02-26 2004-10-15 Optinose As Nasal devices.
AU2002340083A1 (en) 2001-09-28 2003-04-07 Kurve Technology, Inc Nasal nebulizer
GB0207422D0 (en) 2002-03-28 2002-05-08 Optinose As Nasal devices
GB0207817D0 (en) 2002-04-04 2002-05-15 Optinose As Nasal devices
GB0209494D0 (en) 2002-04-25 2002-06-05 Optinose As Nasal devices
US7267121B2 (en) 2004-04-20 2007-09-11 Aerogen, Inc. Aerosol delivery apparatus and method for pressure-assisted breathing systems
IL312785B2 (en) * 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
US12042564B2 (en) * 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
US11773062B2 (en) * 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
WO2021116503A2 (en) * 2020-06-02 2021-06-17 Small Pharma Ltd Deuterated compounds
RU199823U1 (ru) 2020-06-10 2020-09-21 Общество С Ограниченной Ответственностью "Центр Передовых Радиационных Медицинских И Биологических Технологий Устройство для лечения бронхолегочных заболеваний
EP4221682A2 (en) * 2020-10-02 2023-08-09 Cybin IRL Limited Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
EP4031529B1 (en) * 2020-12-01 2023-09-27 Small Pharma Ltd Deuterated or partially deuterated n,n-dimethyltryptamine compounds
MX2023010317A (es) * 2021-03-02 2023-11-09 Mindset Pharma Inc Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos.
AU2022342266B2 (en) * 2021-09-08 2026-03-26 Cybin Irl Limited Combination drug therapies

Similar Documents

Publication Publication Date Title
JP2024533291A5 (enExample)
JP2024540282A5 (enExample)
JP2023526856A5 (enExample)
TW200811116A (en) Compounds
TW201002682A (en) Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
CN100352437C (zh) 哌嗪衍生物、它们的制备方法及其在制备治疗中枢神经系统(cns)疾病的药物中的应用
AU1037897A (en) 3-benzylaminopyrrolidines and -piperidines as tachykinin receptor antagonists
JP2023539113A5 (enExample)
CN100513407C (zh) 三环δ阿片样物质调节剂
JP2023540017A5 (enExample)
JP2025505745A5 (enExample)
JPH05230059A (ja) ベンゾジオキサン誘導体
TWI360540B (en) Tetrahydroisoquinolylsulphonamide derivatives, the
ES2232132T3 (es) Derivados de indolil como agentes serotoninergicos.
CN104610195A (zh) 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
CN1856471A (zh) 3－苯基磺酰基－8－哌嗪－1－基－喹啉的多晶型物
JP2001522847A (ja) ピペリジン誘導体およびそれらのタキキニン拮抗物質としての使用
CN1202164A (zh) 二芳基链烯基胺衍生物
JPWO2008029924A1 (ja) 環状アミノアルキルカルボキサミド誘導体
CN101796027A (zh) N-哌啶-4-基甲基-酰胺衍生物及其作为单胺神经递质再摄取抑制剂的用途
US6608079B1 (en) Indole derivatives and their use as 5-HT1F agonists
WO2008080290A1 (en) Selective m4 receptor antagonist and its medical use
JP2010518053A (ja) アザビシクロアルカン誘導体、これらの調製および治療におけるこれらの使用
CN102850345A (zh) 季铵盐及其药物组合物及其医药用途
WO2014008639A1 (zh) 制备茚达特罗的方法